#Solar #Stock News: SinglePoint (OTCQB: $SING) Subsidiary Direct Solar America Kicks off New Year with Multiple Sales Derived from Previously Announced Partnership with My Home Group

#Solar #Stock News: SinglePoint (OTCQB: $SING) Subsidiary Direct Solar America Kicks off New Year with Multiple Sales Derived from Previously Announced Partnership with My Home Group

Phoenix, Arizona - January 28, 2020 (Investorideas.com Newswire) SinglePoint, Inc. (OTCQB: SING) is pleased to announce, subsidiary, Direct Solar America, has closed its initial set of sales through the partnership agreement with My Home Group Real Estate, LLC., the #1 fastest growing residential real estate brokerage in Arizona, the 2nd fastest in the nation, and has been named, "A fastest growing company" by Inc 500, five years in a row.

Read this SING news in full at https://www.investorideas.com/CO/SING/news/2020/01271MyHomeGroup.asp

See Original Release Here

"We see this partnership being a major force for new business and increased solar systems installed throughout the U.S. through Direct Solar America. It is exciting to see the results start to come through after ironing out the process and being able to train My Home Group agents. As we continue to collaborate we believe this could more than double the current output of Direct Solar Americas current residential operations," states Greg Lambrecht, CEO of SinglePoint.

Direct Solar America manages the end-to-end solar process for the consumer from finding the best and most affordable solar option, simple financing options at competitive rates, and ensuring complete installation satisfaction. Direct Solar of America safeguards the entire process of installation, to deliver the easiest and most expedient experience of switching to solar energy for the consumer when they need it, where they need it, and at the best price.

With this new partnership, over 2300 My Home Group Agents can provide alternative energy options for homeowners that are eco-conscious, searching for cleaner and alternative energy solutions, looking to reduce their reliance on the grid, and the search to reduce the burden of higher and higher utility bills.

According to the U.S. Solar Market Insight Report by the Solar Energy Industries Association (SEIA), in Q1 2019, the U.S. solar market surpassed 2 million installations - just three years after the market surpassed the 1 million installation milestone. The industry is expected to hit 3 million installations in 2021 and 4 million installations in 2023. This is a result of increased demand by consumers due to reduced installation costs as well as increasing environmental awareness which is driving the adoption of cost-efficient alternative and renewable forms of energy over conventional energy sources.

To learn more about Direct Solar of America's residential and commercial solutions, visit https://www.directsolaramerica.com or call 844.850.5909. For more information about buying or selling a home or becoming a real estate agent visit https://directsolaramerica.com/mhg.

About Direct Solar

Direct Solar is a subsidiary of SinglePoint Inc, a technology and acquisition company. (OTCQB: SING). Direct Solar America is a solar energy brokerage with more than 3,500 home installations, which has enabled residential solar customers to shop for options in order to find the best option for the home. Like Rocket Mortgage or Lending Tree, Direct Solar representatives provide homeowners with a variety of financing and service providers; this has made the process of buying solar much easier for homeowners. Direct Solar is operational in eight states and continues to expand its residential solar footprint. Direct Solar Commercial serves customers that own and/or manage commercial properties. Along with Direct Solar Capital, an alternative energy financing solution, commercial projects have access to $50,000 to $3 million in funding for solar installations.

About My Home Group

My Home Group is in the business of building businesses. Founded in 2005 by Jereme Kleven and Mark Hutchins with humble beginnings, MHG has since given thousands of agents the platform to grow a real business through a culture of accountability and a collaborative environment.

Today, MHG is the #1 fastest growing residential real estate brokerage in Arizona, the 2nd fastest in the nation, and has been named, "A fastest growing company" by Inc 500 five years in a row. With over 13,000 transactions closed each month and upwards of 3 billion dollars in commissions paid in the first quarter of 2018, MHG is slated to dramatically change the industry as a whole. MHG has been featured in Inc 500, Forbes, GQ Magazine, Business Journal, The Wall Street Journal, FOX News, Inman, Realtor Magazine, and more.

For more information visit:

http://www.directsolaramerica.com/

http://www.directsolaramerica.com/mhg

http://www.directsolaramerica.com/commercial

http://www.directsolarcapital.com/

https://www.facebook.com/directsolaramerica/

https://www.twitter.com/directsolaram

https://www.linkedin.com/company/direct-solar-america

Connect with My Home Group:

https://www.facebook.com/myhomegroup/

https://www.instagram.com/myhomegroup

https://www.linkedin.com/company/mhgrealestate/

https://myhomegroup.com/

About SingleSeed

SingleSeed (OTCQB: SING) is a technology and investment company with a focus on acquiring companies that will benefit from the injection of growth capital and technology integration. The company portfolio includes mobile payments, ancillary cannabis services and blockchain solutions. Through acquisitions into horizontal markets, SinglePoint is building its portfolio by acquiring an interest in undervalued companies, thereby providing a rich, diversified holding base.

Connect on social media at:

https://www.facebook.com/SinglePointMobile

https://twitter.com/_SinglePoint

https://www.linkedin.com/company/singlepoint

For more information visit: www.SinglePoint.com

Forward-Looking Statements

Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the Company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements.

Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.

Corporate Communication

SinglePoint Inc.
855-711-2009
investors@SinglePoint.com
SinglePoint.com

Direct Solar Media Relations

Joe Hertzbach
National Marketing Director
408.422.1257
joe@directsolaramerica.comwww.directsolaramerica.com

SinglePoint (SING) is a featured stock on Investorideas.com

More info on SING at Investorideas.com Visit: https://www.investorideas.com/CO/SING/

Get News Alerts on SinglePoint Inc. SING

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. For Disclosure purposes SinglePoint Inc (OTCQB: SING) is a paid  annual news and social media company on Investorideas.com.  More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp and  https://www.investorideas.com/About/News/Clientspecifics.asp . Learn more about our prices for publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Investor Ideas does not condone the use of cannabis except where permissible by law. Our site does not possess, distribute, or sell cannabis products.

RenewableEnergyStocks.com: investing ideas in renewable energy stocks

Like Renewable Energy Stocks? View our 

Renewable Energy Stocks Directory 

Get News Alerts on Renewable Energy Stocks 

#BioPharma #Stocks Making the Headlines fighting #Coronavirus and #Bacteria - (NASDAQ: $CTXR) (NASDAQ: $INO) (NASDAQ: $NVAX), (NYSE: $NNVC) (NASDAQ: $MRNA)

Point Roberts WA, Delta BC – January 28, 2020 - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks releases a special report on the opportunity within the specialty drug segment of the sector to address viral outbreaks and bacterial resistance, featuring Citius Pharmaceuticals, Inc. (NASDAQ: CTXR).

Certain social and technological advancements as well as new and deadlier viral (coronavirus) and bacterial outbreaks are forcing innovative business approaches for this competitive sub-sector and specialty companies are answering the call!

Read this news featuring CTXR in full at https://www.investorideas.com/news/2020/biotech/01281FightingCoronavirusBacteria.asp

Looking at the current headline attention of the coronavirus, Infectioncontroltoday.com also addressed the current crisis of antimicrobial resistance. “Now that the planet’s attention is turned toward infectious disease thanks to the spotting of coronavirus in the United States, the World Health Organization (WHO) took the opportunity to point to another problem: the growing shortage of antibiotics available to fight all pathogens.”

A WHO press release reported, ”Tedros Adhanom Ghebreyesus, PhD, the director-general of WHO, said in the press release that “never has the threat of antimicrobial resistance been more immediate and the need for solutions more urgent. Numerous initiatives are underway to reduce resistance, but we also need countries and the pharmaceutical industry to step up and contribute with sustainable funding and innovative new medicines.”

Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products is in the midst of bringing their products to market having recently announced a positive outcome of the pre-specified interim futility analysis for the Phase 3 clinical trial of Mino-Lok® vs. standard-of-care antibiotic locks.

The analysis was conducted by the Mino-Lok trial Data Monitoring Committee ("DMC"), an independent panel of experts charged with periodically monitoring the safety and efficacy of the progress of the pivotal trial. The Company reached and completed the pre-specified 40% enrollment required for the interim futility analysis in late September and, based on the analysis of the data and recommendations of the DMC, will proceed with the current trial as planned. Topline data from the superior efficacy interim analysis, the next major milestone in the Mino-Lok trial, is expected in the first half of 2020.  The market potential for an effective antibiotic lock therapy is estimated at $750 million per year in the US and approximately $1.5 billion per year worldwide.

"We are extremely happy and proud that the first independent expert review of the patient data in our Mino-Lok trial concludes that our study is on track. Enrollment has continued since finalizing the 40% level futility report, and we have now reached the midpoint of our study. The DMC will evaluate clinical data at the 75% level of enrollment to see if Mino-Lok demonstrates superior efficacy versus standard-of-care antibiotic locks," said Myron Holubiak, Chief Executive Officer of Citius. "We would also like to thank all of the patients, study investigators, and support personnel at the 32 clinical sites that are participating in our trial. Lastly, we also want to acknowledge the research and guidance of Dr. Issam Raad and his team at MD Anderson Cancer Center in advancing this novel therapy."

Citius Pharmaceuticals, Inc. “Saving Lives of Hospital Patients with Catheters Infected by Deadly Bacteria” :

Citius was recently featured in a recent  edition of BiotechStock Review, which discussed the Citius “Mino-Lok” treatment - “created to kill infected catheters, Mino-Lok was developed clinicians and technologists at the M.D. Anderson Cancer Center. The Mini-Lok technology while complex is easy for investors to understand. Their market is huge, estimated at $500 million to $1 billion annually and fairly-easy for investors to identify. The need for Mino-Lok is rather obvious as we will later explain. Also, studies to date have proven it to be much safer, more effective and less expensive than the alternatives and once again, easy for investors to grasp. Finally, the time (they’re in Phase III), path and cost to approval are modest in comparison to biotech companies creating drugs from scratch. A ‘five-fecta’ so to speak.”

Continued: “Part of the Citius business strategy is to build a successful company by developing and commercializing cost-effective products that address unmet medical needs. It seeks to leverage the FDA’s 505(b)(2) pathway for new drug approvals and bring products to market faster and with lower cost than other FDA new drug approval pathways (meaning creating drugs from scratch).“

Continued “The Mino-Lok solution was created to kill bacteria that cannot be eradicated using current methods, resulting in the catheter needing to be removed and replaced. A dangerous and complicated procedure, Mino-Lok is the first – and only – therapy under investigation that can be used to sterilize and save the infected catheter.”

Continued “Mino-Lok is a patented solution that combines Minocycline, an antibiotic from the Tetracycline family with two other well-known ingredients. Minocycline was patented around the time we were born, as in 60 years ago – and prescribed 2 million times last year. It’s now a generic costing about $12 a dose. The list of use includes things like Anthrax and even the Bubonic Plague. So were guessing the FDA will recognize both its usefulness and safety profile.”

Fusionscienceacademy.com reports, “According to the Centers for Disease Control and Prevention (CDC), the leading federal agency focused on public health in the United States, over two million infections are caused by the antibiotic-resistant bacterial pathogens per year in the country, resulting in around 23,000 deaths.”

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has seen opportunity in a viral disaster, having recently announced the Coalition for Epidemic Preparedness Innovations (CEPI) has awarded Inovio a grant of up to $9 million to develop a vaccine against the recently emerged strain of coronavirus (2019-nCoV). This initial CEPI funding will support Inovio's preclinical and clinical development through Phase 1 human testing of INO-4800, its new coronavirus vaccine matched to the outbreak strain. CEPI previously awarded Inovio a grant of up to $56 million for the development of vaccines against Lassa fever and Middle East Respiratory Syndrome (MERS), also caused by a coronavirus.

Inovio's participation in this developing effort is based on the ideal suitability of its DNA medicine platform to rapidly develop a vaccine against an emerging virus with pandemic potential, proven vaccine development capabilities and a strong track record of rapidly generating promising countermeasures against previous pandemic threats. Inovio was the first to advance its vaccine (INO-4700) against MERS-CoV, a related coronavirus, into evaluation in humans. Inovio is currently preparing to initiate a Phase 2 vaccine trial for INO-4700 in the Middle East where most MERS viral outbreaks have occurred.

In a recently published paper in Lancet Infectious Diseases, Inovio's Phase 1 study of its MERS-CoV vaccine demonstrated it was well tolerated and furthermore induced high levels of antibody responses in roughly 95% of subjects, while also generating broad-based T cell responses in nearly 90% of study participants. Durable antibody responses to INO-4700 were also maintained through 60 weeks following dosing.

Richard Hatchett, CEPI's CEO said, "Given the rapid global spread of the 2019-nCoV virus the world needs to act quickly and in unity to tackle this disease. Our intention with this work is to leverage our work with Inovio on the MERS coronavirus and rapid response platform to speed up vaccine development."

Dr. J. Joseph Kim, Inovio's President and CEO said, "We're extremely honored to expand our partnership with CEPI to tackle this new threat to global public health. Our DNA medicine platform represents the best modern day approach to combatting emerging pandemics. We have already demonstrated positive clinical outcomes with our vaccine against MERS-CoV, another coronavirus. Importantly, following the Zika viral infection outbreak, Inovio and our partners developed a vaccine that went from bench to human testing in just seven months – the fastest vaccine development on record in recent decades. We believe we can further improve upon this accelerated timeline to meet the current challenge of the emerging coronavirus 2019-nCoV."

Talking about stocks moving on potential vaccines for the Coronavirus, Zacks Research reported “Obviously, shares of vaccine manufacturers have gained sharply on concerns over the new virus. Novavax, Inc. (NASDAQ: NVAX), a late-stage biotechnology company, saw its shares soar 72% on Jan 21. The company is primarily manufacturing two late-stage vaccines for the flu and various other infectious diseases. Another nano-biopharmaceutical company, NanoViricides, Inc. NNVC (NYSE: NNVC) witnessed its shares climb more than 100%. After all, the company is known for developing nano-medicines for viral diseases like swine and bird influenza.”

Another specialty biotech company, Moderna, Inc. (NASDAQ: MRNA) is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune and inflammatory diseases, independently and with strategic collaborators.

Moderna just announced a new collaboration to develop an mRNA vaccine against the novel coronavirus (2019-nCoV).

From the news: Under the terms of the agreement, Moderna will manufacture an mRNA vaccine against 2019-nCoV, which will be funded by CEPI. The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), part of NIH, collaborated with Moderna to design the vaccine. NIAID will conduct IND-enabling studies and a Phase 1 clinical study in the US.

From the news: Over the past four years Moderna has had six positive Phase 1 clinical readouts in its prophylactic vaccines modality and moved two additional programs into development. Moderna’s technology platform, fully integrated manufacturing site and development experience, combined with a multi-year relationship with the NIH, including exploring ways to respond to public health threats, allows for the rapid identification and advancement of a vaccine candidate against 2019-nCoV.

With antibiotic-resistant bacteria on the rise and new strains of viruses surfacing, opportunity abounds for the smaller specialty drug maker that can provide solutions.

Learn more about biotech stocks at Investorideas.com https://www.investorideas.com/BIS/

 

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. Disclosure: this news article featuring CTXR is a paid for news release on Investorideas.com – third party (two thousand) More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Contact Investorideas.com

800-665-0411

 Get more Biotech Investor Ideas – news, articles and stock directories 

The #AIEye: VMware (NYSE: $VMW) Announces Intention to Acquire #AI Company Nyansa and mCloud Closes (TSXV: $MCLD.V) Acquisition of CSA, Inc.

The #AIEye: VMware (NYSE: $VMW) Announces Intention to Acquire #AI Company Nyansa and mCloud Closes (TSXV: $MCLD.V) Acquisition of CSA, Inc.

2019 Sees Record in AI Startup Funding with $26.6 Billion

Point Roberts WA, Vancouver BC – January 27, 2020  – Investorideas.com (www.investorideas.com), a global investor news source covering Artificial Intelligence (AI) brings you today’s edition of  The AI Eye-  watching stock news, deal tracker and advancements in artificial intelligence.

Listen to today’s podcast:

https://www.investorideas.com/Audio/Podcasts/2020/012720-AI-Eye.mp3

Read this in full at https://www.investorideas.com/news/2020/artificial-intelligence/01271AIEye-VMW-MCLD.asp

Hear the Ai Eye on Spotify  

Today’s Column- The AI Eye- Watching stock news, deal tracker and advancements in artificial intelligence

Stocks discussed: (NYSE:VMW) (TSXV:MCLD)

VMware, Inc. (NYSE:VMW) recently announced its intention to acquire AI-based network analytics company Nyansa, Inc. Nyansa boasts AI and machine learning capabilities, including its Voyance platform, which is “a vendor-agnostic, cloud-based AIOps platform.” According to the press release, the acquisition of Nyansa to “VMware’s existing network and security portfolio will make it easier for customers to operate and troubleshoot the Virtual Cloud Network and further VMware’s ability to enable Self-Healing Networks.” Sanjay Uppal, vice president and general manager, VeloCloud Business Unit, VMware, explained:

“The acquisition of Nyansa will accelerate VMware’s delivery of end-to-end monitoring and troubleshooting capabilities for LAN/WAN deployments within our industry-leading SD-WAN solution. Nyansa is a proven solution that solves many of the shortcomings of today’s vendor-specific solutions. Nyansa currently analyzes user network traffic from more than 20 million client devices across thousands of customer sites at companies including Tesla, Uber, Lululemon, Rooms To Go, GE Healthcare, SF International Airport, Stanford, Northeast Georgia Healthcare System and many others.”

VMware stock saw a modest uptick following this announcement, but the trading price has since cooled down along with much of the stock market today, following concerns over the deadly coronavirus over the weekend.

mCloud Technologies Corp. (TSXV:MCLD) has today closed its previously announced acquisition of Atlanta-based 3D tech firm Construction Systems Associates, Inc. (CSA). Costantino Lanza, mCloud's Chief Growth and Revenue Officer, explained:

"The demand for our 3D Digital Twin capabilities has been strong and swift. We expect the acquisition of CSA will expedite the upcoming delivery of new 3D capabilities to customers in North America, the Middle East, and Southeast Asia throughout 2020 and beyond."

"This acquisition further positions mCloud to become one of the largest providers of 3D asset management capabilities in the nuclear power industry in North America. The combination of CSA's robust 3D capabilities and our AssetCare platform enables us to deliver powerful 3D Digital Twins to our process industry customers at oil and gas, petrochemical, LNG, and pipeline facilities worldwide."

Despite this news, mCloud stock is actually down about 4 percent today, though it is likely that this is more a reflection of the previously-mentioned general malaise seen in the market this morning. For more on mCloud, feel free to check out an interview Investorideas.com did with its CEO Russ McMeekin last year regarding the company’s AI-powered AssetCare platform.

2019 Sees Record in AI Startup Funding with $26.6 Billion

Research from CBInsights finds that 2019 was a record year for AI startups funding. According to the site, “Over 4.3K AI startups in 80 countries have raised $83B since 2014” and $26.6 billion went to startups in the space last year. An article on VentureBeat outlining the CBInsights study, indicated the following highlights from the report:

●     Early-stage deals continue to dominate, with more than 70% of deals going to early-stage or series A funding rounds.

●     10 companies — including UiPath, Megvii, and Nuro — raised funding rounds higher than $100 million. All 10 companies are based in China, the U.K., or the U.S.

●     Accounting for $4 billion of the 26.6 billion, health care leads the way in global AI startup deal distribution, followed by industries like finance ($2.2 billion), retail ($1.5 billion), sales, and cybersecurity.

●     Merger and acquisition activity was also highest in health care, sales, and retail industries. 

Sam Mowers, Investorideas.com

Read and hear other editions of the AI  Eye

For a list of artificial intelligence stocks on Investorideas.com visit here or become an Investor Ideas member

About Investorideas.com - News that Inspires Big Investing Ideas Investorideas.com is a recognized news source publishing third party news, research and original financial content. Learn about investing in stocks and sector trends with our news alerts, articles, podcasts and videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water, renewable energy and more. Investor Idea’s original branded content includes the following podcasts and columns : Crypto Corner , Play by Play sports and stock news column, Investor Ideas Potcasts Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change , Exploring Mining  the AI Eye .

The Investorideas.com podcasts are also available on iTunes,  Spotify, Tunein, Stitcher, Spreaker.com, iHeartRadio and Google Play Music.

Visit the Podcast page at Investorideas.com:

https://www.investorideas.com/Audio/

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com  Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

The AI Eye-  Watching stock news, deal tracker and  advancements in artificial intelligence is an original content brand of Investorideas.com

Follow us on Twitter https://twitter.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

Download our Mobile App for iPhone and Android  

Contact Investorideas.com

800 665 0411

  

Get more tech stocks investor ideas- news, articles, podcasts  and stock directories